,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2014-06-10 02:30:00,"Baxter International Inc. ( BAX ) recently presented clinical data supporting the safety and efficacy of its VIVIA Haemodialysis (HD) System, designed to deliver High Dose HD in the home environment.",0.7050381898880005,0.012432177551090717,0.2825295925140381,positive,0.6926060318946838
1,2014-06-10 02:30:00,"Following the release, shares of BAX, however, dropped by a marginal 0.1% to close at $73.64 yesterday.",0.01731432043015957,0.9729558229446411,0.009729951620101929,negative,-0.955641508102417
2,2014-06-10 02:30:00,"BAX shared its VIVIA HD system data for the first time with the European nephrology community at the 51st Congress of the European Renal Association and European Dialysis and Transplant Association (ERA-EDTA), which took place from May 31 to Jun 3 in Amsterdam.",0.4767587184906006,0.010391933843493462,0.5128493309020996,neutral,0.46636679768562317
3,2014-06-10 02:30:00,The VIVIA HD System is designed to support High Dose HD therapy - a more frequent and extended duration treatment administered in the form of short daily treatments or nocturnal treatments.,0.10599429160356522,0.005505243316292763,0.888500452041626,neutral,0.1004890501499176
4,2014-06-10 02:30:00,The VIVIA HD System's user-friendly features allow a greater number of haemodailysis patients to access High Dose HD therapy in their home environment.,0.6063234806060791,0.010455320589244366,0.38322126865386963,positive,0.5958681702613831
5,2014-06-10 02:30:00,The system also includes a fully integrated wireless connectivity platform that allows physicians to comprehensively monitor home therapy remotely.,0.3639451861381531,0.007958649657666683,0.6280962228775024,neutral,0.3559865355491638
6,2014-06-10 02:30:00,The VIVIA HD System received CE Mark approval for a European launch in Dec 2013.,0.6914668679237366,0.010263431817293167,0.29826968908309937,positive,0.6812034249305725
7,2014-06-10 02:30:00,"Year-to-date, the system is being introduced on a limited basis in select European dialysis clinics.",0.0874832347035408,0.005391577258706093,0.9071252346038818,neutral,0.08209165930747986
8,2014-06-10 02:30:00,BAX plans to expand the launch to other European countries in 2015.,0.7918689250946045,0.0123455710709095,0.1957855075597763,positive,0.7795233726501465
9,2014-06-10 02:30:00,"The first in-human study was a prospective, single arm clinical study conducted in haemodialysis centers in the U.S.",0.06027970090508461,0.005583509802818298,0.9341367483139038,neutral,0.05469619110226631
10,2014-06-10 02:30:00,"Under the study, 22 patients received four HD treatments with the VIVIA HD system every week for 10 weeks.",0.1790006160736084,0.06782637536525726,0.7531729936599731,neutral,0.11117424070835114
11,2014-06-10 02:30:00,"In the second prospective, single arm clinical study carried out in haemodialysis centres in Canada, 17 patients received nocturnal HD treatments with the VIVIA HD system 3 times a week for 6 weeks.",0.14749741554260254,0.10566824674606323,0.746834397315979,neutral,0.04182916879653931
12,2014-06-10 02:30:00,"Results from both the studies demonstrated the system's capability to accurately remove excess body fluid, as shown by a strong correlation established between fluid weights removed and weight change.",0.7192355990409851,0.018359486013650894,0.2624049186706543,positive,0.7008761167526245
13,2014-06-10 02:30:00,The research further confirmed the system's ability to clear uremic toxins safely and reliably.,0.884433925151825,0.014089382253587246,0.10147666186094284,positive,0.8703445196151733
14,2014-06-10 02:30:00,"Apart from its clinical advantages, additional data presented at the congress holds the VIVIA HD System as a potentially more sustainable and cost-effective therapy.",0.8408983945846558,0.014089529402554035,0.14501206576824188,positive,0.8268088698387146
15,2014-06-10 02:30:00,Results from another study established that the VIVIA HD System emitted the lowest amount of carbon compared to a currently-available home HD device and a conventional in-centre HD device that can be used for home dialysis.,0.23246914148330688,0.08141318708658218,0.6861177086830139,neutral,0.1510559618473053
16,2014-06-10 02:30:00,"By means of a lower carbon footprint, the system is set to make a significant impact in delivering sustainable HD therapies.",0.8311706185340881,0.012519924901425838,0.15630941092967987,positive,0.8186507225036621
17,2014-06-10 02:30:00,"Furthermore, other studies found High Dose HD at home to be cost effective when compared with conventional in-centre HD devices.",0.8825606107711792,0.016082994639873505,0.10135640949010849,positive,0.8664776086807251
18,2014-06-10 02:30:00,"Two separate analyses of High Dose HD in the U.K. confirmed that increased usage could lead to considerable cost savings and an increase in quality-adjusted, life-years gained.",0.9203956127166748,0.01519025769084692,0.06441415101289749,positive,0.9052053689956665
19,2014-06-10 02:30:00,"Currently, BAX retains a Zacks Rank #3 (Hold).",0.033690694719552994,0.00905874464660883,0.9572505950927734,neutral,0.02463195100426674
20,2014-06-10 02:30:00,"Some better-ranked medical product stocks worth considering are Cardica Inc. ( CRDC ), Eagle Pharmaceuticals Inc. ( EGRX ) and NeuroMetrix Inc. ( NURO ).",0.4816845655441284,0.01749052107334137,0.5008249282836914,neutral,0.46419405937194824
21,2014-06-10 02:30:00,All these stocks carry a Zacks Rank #2 (Buy).,0.1801605224609375,0.0149730509147048,0.8048664331436157,neutral,0.16518747806549072
22,2014-06-10 02:30:00,Want the latest recommendations from Zacks Investment Research?,0.03539300337433815,0.011573811061680317,0.9530332088470459,neutral,0.023819193243980408
23,2014-06-10 02:30:00,"Today, you can download 7 Best Stocks for the Next 30 Days.",0.05069372057914734,0.007019792217761278,0.9422864317893982,neutral,0.04367392882704735
24,2014-06-10 02:30:00,"Click to get this free report

To read this article on Zacks.com click here.",0.020684564486145973,0.03315984085202217,0.9461556077003479,neutral,-0.012475276365876198
25,2014-06-10 02:30:00,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.010204566642642021,0.015637893229722977,0.9741575717926025,neutral,-0.0054333265870809555
